Coherus Oncology, Inc. Common Stock
CHRS Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of CHRS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Shri Thanedar House / D | Sale $15,001 - $50,000 | Jan 23, 2023 |
CHRS Stock Insider Trading Activity
Follow @QuiverQuant for major insider updates
---
Closing Price
Purchase
Sale
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
CHRS Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
CHRS Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in CHRS holdings by institutional investors
Quarterly net insider trading by CHRS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Backtest Start Date
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Subscribe to Quiver Premium for insider trading alerts
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$95,000 Jul 28, 2026 Issue: Health Issues Government Issues
-
$80,000 May 18, 2026 Issue: Health Issues Government Issues
-
$80,000 Mar 09, 2026 Issue: Health Issues Government Issues
-
$125,000 Aug 18, 2025 Issue: Health Issues Government Issues
-
$125,000 Aug 18, 2025 Issue: Health Issues Government Issues
-
$65,000 Mar 24, 2025 Issue: Health Issues Government Issues
-
$65,000 Mar 24, 2025 Issue: Health Issues Government Issues
-
$45,000 Sep 26, 2024 Issue: Government Issues Health Issues
-
$87,500 Sep 26, 2024 Issue: Government Issues Health Issues
-
$45,000 Jan 29, 2024 Issue: Intelligence Defense
-
$10,000 Jan 22, 2024 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$40,000 Jan 20, 2024 Issue: Pharmacy Health Issues Medicare/Medicaid
-
$45,000 Jan 10, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Dec 31, 2023 Issue: Pharmacy
-
$275,000 Oct 20, 2023 Issue: Government Issues Health Issues
-
$275,000 Jul 19, 2023 Issue: Government Issues Health Issues
-
$275,000 Jan 19, 2023 Issue: Government Issues Health Issues
-
$250,000 Oct 18, 2022 Issue: Government Issues Health Issues
-
$250,000 Jul 14, 2022 Issue: Government Issues Health Issues
-
$200,000 Mar 29, 2022 Issue: Government Issues Health Issues
-
$160,000 Jan 21, 2022 Issue: Government Issues Health Issues
-
$130,000 Oct 22, 2021 Issue: Government Issues Health Issues
-
$100,000 Aug 13, 2021 Issue: Health Issues Government Issues
-
$100,000 Apr 20, 2021 Issue: Government Issues Health Issues
-
$75,000 Jan 04, 2021 Issue: Health Issues Government Issues
-
$50,000 Nov 04, 2020 Issue: Health Issues Government Issues
-
$60,000 Jul 03, 2020 Issue: Pharmacy
-
$60,000 Apr 12, 2020 Issue: Pharmacy
-
$60,000 Jan 08, 2020 Issue: Pharmacy
-
$60,000 Oct 13, 2019 Issue: Pharmacy
-
$60,000 Jul 11, 2019 Issue: Pharmacy
-
$60,000 Apr 09, 2019 Issue: Pharmacy
-
$60,000 Jan 13, 2019 Issue: Pharmacy
-
$60,000 Oct 15, 2018 Issue: Pharmacy
-
$60,000 Jan 02, 2018 Issue: Pharmacy Health Issues Medicare/Medicaid
-
$80,000 Dec 31, 2017 Issue: None
-
$120,000 Oct 11, 2017 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Budget/Appropriations
-
$120,000 Jul 12, 2017 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations
-
$120,000 Apr 14, 2017 Issue: Health Issues Copyright/Patent/Trademark Budget/Appropriations Medicare/Medicaid
-
$120,000 Dec 19, 2016 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Budget/Appropriations
-
$120,000 Oct 17, 2016 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations
-
$120,000 Jul 14, 2016 Issue: Medicare/Medicaid Budget/Appropriations Copyright/Patent/Trademark Health Issues
-
$120,000 Apr 18, 2016 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$40,000 Oct 19, 2015 Issue: Health Issues
Former government officials who have lobbied for CHRS
CHRS Estimated quarterly lobbying spending
CHRS Revenue by Segment or Geography
By Segment
By Geography
CHRS Income Statement
CHRS Balance Sheet
CHRS Cash Flow
U.S. Patents
New CHRS patent grants
-
Patent Title: Systems and methods for producing sterile injection devices Sep. 12, 2023
-
Patent Title: Stable aqueous formulations of aflibercept Jun. 06, 2023
-
Patent Title: Stable protein compositions and methods of their use Feb. 21, 2023
-
Patent Title: Method of filling a container with no headspace Feb. 14, 2023
-
Patent Title: Stable aqueous formulations of aflibercept Aug. 30, 2022
-
Patent Title: Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy Aug. 02, 2022
-
Patent Title: Methods for making recombinant proteins Jul. 26, 2022
-
Patent Title: Ppary agonist for treatment of progressive supranuclear palsy Feb. 22, 2022
-
Patent Title: High concentration formulations of adalimumab Jan. 25, 2022
-
Patent Title: Etanercept formulations stabilized with metal ions Oct. 05, 2021
-
Patent Title: Etanercept formulations stabilized with amino acids Sep. 28, 2021
-
Patent Title: Method of filling a container with no headspace Jul. 27, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield May. 11, 2021
-
Patent Title: Method of manufacturing a protein by perfusion in media with a low amino acid concentration May. 11, 2021
-
Patent Title: Etanercept formulations stabilized with sodium chloride May. 11, 2021
-
Patent Title: Method of reducing formation of etanercept aggregates or fragments Apr. 27, 2021
-
Patent Title: Method of reducing formation of etanercept aggregates or fragments Apr. 20, 2021
-
Patent Title: Stable aqueous etanercept composition Apr. 20, 2021
-
Patent Title: Correctly folded etanercept composition Apr. 13, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 23, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 23, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 23, 2021
-
Patent Title: Correctly folded etanercept in high purity and excellent yield Mar. 16, 2021
-
Patent Title: Stable aqueous etanercept composition Jan. 12, 2021
-
Patent Title: Etanercept formulations exhibiting marked reduction in sub-visible particles Nov. 03, 2020
-
Patent Title: Etanercept formulations stabilized with combinations of sugars and polyols Apr. 17, 2018
-
Patent Title: Stable aqueous formulations of adalimumab Jan. 09, 2018
-
Patent Title: Stable aqueous formulations of adalimumab Nov. 07, 2017
-
Patent Title: Etanercept formulations stabilized with metal ions Oct. 31, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Oct. 17, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Oct. 10, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Oct. 10, 2017
-
Patent Title: Etanercept formulations stabilized with xylitol Sep. 26, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Sep. 26, 2017
-
Patent Title: Perfusion method for manufacturing etanercept Sep. 19, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Sep. 12, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Aug. 22, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Aug. 15, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Aug. 15, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Aug. 08, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Aug. 08, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Jul. 18, 2017
-
Patent Title: Stable aqueous formulations of adalimumab Jun. 20, 2017
-
Patent Title: Stable aqueous formulations of etanercept May. 30, 2017
-
Patent Title: Etanercept formulations stabilized with xylitol Jul. 19, 2016
-
Patent Title: Stable aqueous formulations of adalimumab Jul. 05, 2016
-
Patent Title: Stable aqueous formulations of adalimumab May. 24, 2016
-
Patent Title: Stable aqueous formulations of adalimumab May. 17, 2016
-
Patent Title: Stable aqueous formulations of adalimumab May. 17, 2016
-
Patent Title: Etanercept formulations stabilized with combinations of sugars and polyols Apr. 05, 2016
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded to CHRS from public contracts
CHRS News
Recent insights relating to CHRS
CNBC Recommendations
Recent picks made for CHRS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CHRS
CHRS Analyst Ratings
CHRS Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
CHRS Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $CHRS stock a Buy, Sell, or Hold?
- What is the price target for $CHRS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
CHRS Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $CHRS stock?
- Who owns the most shares of $CHRS stock?
- What funds own $CHRS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
CHRS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CHRS Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
About CHRS
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
- Address Redwood City, CA
- Market Cap 194.7 million
- Employees 144
- Industrial Classification Biological Products, (No Diagnostic Substances)
Coherus Oncology, Inc. Common Stock (CHRS) Historical Stock Prices
Coherus Oncology, Inc. Common Stock (CHRS) closed at $1.26 on September 23, 2026. Over the past year its adjusted close ranged from $1.10 to $2.51. Daily prices go back to November 6, 2014, 2,986 trading days in all.
- 1 month-7.35%
- 3 months-17.11%
- Year to date-11.27%
- 1 year-19.23%
- 3 years-71.75%
- 5 years-92.89%
- Max-90.01%
See every congressional and insider trade on the CHRS price chart
Quiver Premium charts CHRS's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | 1.30 | 1.31 | 1.21 | 1.26 | 1.26 | 1,617,123 |
| Sep 22, 2026 | 1.39 | 1.39 | 1.22 | 1.30 | 1.30 | 4,537,053 |
| Sep 21, 2026 | 1.35 | 1.43 | 1.30 | 1.37 | 1.37 | 1,489,493 |
| Sep 18, 2026 | 1.23 | 1.35 | 1.23 | 1.35 | 1.35 | 3,124,885 |
| Sep 17, 2026 | 1.26 | 1.27 | 1.18 | 1.23 | 1.23 | 1,886,521 |
| Sep 16, 2026 | 1.34 | 1.35 | 1.21 | 1.22 | 1.22 | 1,290,622 |
| Sep 15, 2026 | 1.38 | 1.39 | 1.32 | 1.33 | 1.33 | 761,960 |
| Sep 14, 2026 | 1.34 | 1.43 | 1.34 | 1.43 | 1.43 | 1,274,940 |
| Sep 11, 2026 | 1.38 | 1.38 | 1.32 | 1.33 | 1.33 | 529,193 |
| Sep 10, 2026 | 1.33 | 1.36 | 1.30 | 1.34 | 1.34 | 1,019,588 |
| Sep 9, 2026 | 1.34 | 1.38 | 1.31 | 1.32 | 1.32 | 840,616 |
| Sep 8, 2026 | 1.40 | 1.43 | 1.36 | 1.37 | 1.37 | 549,199 |
| Sep 4, 2026 | 1.38 | 1.44 | 1.38 | 1.42 | 1.42 | 306,060 |
| Sep 3, 2026 | 1.42 | 1.43 | 1.36 | 1.37 | 1.37 | 437,196 |
| Sep 2, 2026 | 1.37 | 1.44 | 1.35 | 1.42 | 1.42 | 621,492 |
| Sep 1, 2026 | 1.36 | 1.40 | 1.35 | 1.37 | 1.37 | 695,157 |
| Aug 31, 2026 | 1.39 | 1.41 | 1.30 | 1.35 | 1.35 | 1,128,490 |
| Aug 28, 2026 | 1.45 | 1.48 | 1.40 | 1.41 | 1.41 | 605,087 |
| Aug 27, 2026 | 1.43 | 1.48 | 1.41 | 1.46 | 1.46 | 788,317 |
| Aug 26, 2026 | 1.37 | 1.46 | 1.34 | 1.45 | 1.45 | 896,540 |
| Aug 25, 2026 | 1.36 | 1.41 | 1.31 | 1.37 | 1.37 | 1,297,214 |
| Aug 24, 2026 | 1.43 | 1.43 | 1.35 | 1.36 | 1.36 | 1,046,359 |
| Aug 21, 2026 | 1.32 | 1.44 | 1.31 | 1.42 | 1.42 | 1,567,515 |
| Aug 20, 2026 | 1.31 | 1.34 | 1.27 | 1.32 | 1.32 | 740,186 |
| Aug 19, 2026 | 1.38 | 1.41 | 1.29 | 1.33 | 1.33 | 3,038,144 |
| Aug 18, 2026 | 1.26 | 1.36 | 1.22 | 1.34 | 1.34 | 3,477,723 |
| Aug 17, 2026 | 1.20 | 1.20 | 1.13 | 1.15 | 1.15 | 1,264,551 |
| Aug 14, 2026 | 1.16 | 1.21 | 1.14 | 1.20 | 1.20 | 648,327 |
| Aug 13, 2026 | 1.18 | 1.20 | 1.13 | 1.14 | 1.14 | 1,059,989 |
| Aug 12, 2026 | 1.21 | 1.25 | 1.17 | 1.17 | 1.17 | 1,155,915 |
| Aug 11, 2026 | 1.25 | 1.26 | 1.18 | 1.21 | 1.21 | 968,344 |
| Aug 10, 2026 | 1.33 | 1.34 | 1.23 | 1.24 | 1.24 | 978,460 |
| Aug 7, 2026 | 1.27 | 1.40 | 1.24 | 1.27 | 1.27 | 1,600,233 |
| Aug 6, 2026 | 1.39 | 1.46 | 1.13 | 1.26 | 1.26 | 3,721,767 |
| Aug 5, 2026 | 1.48 | 1.52 | 1.44 | 1.45 | 1.45 | 999,321 |
| Aug 4, 2026 | 1.43 | 1.50 | 1.43 | 1.48 | 1.48 | 617,715 |
| Aug 3, 2026 | 1.42 | 1.46 | 1.41 | 1.44 | 1.44 | 477,295 |
| Jul 31, 2026 | 1.48 | 1.48 | 1.40 | 1.41 | 1.41 | 437,184 |
| Jul 30, 2026 | 1.42 | 1.49 | 1.42 | 1.47 | 1.47 | 509,553 |
| Jul 29, 2026 | 1.44 | 1.48 | 1.40 | 1.41 | 1.41 | 570,978 |
| Jul 28, 2026 | 1.46 | 1.47 | 1.42 | 1.44 | 1.44 | 387,626 |
| Jul 27, 2026 | 1.46 | 1.50 | 1.44 | 1.46 | 1.46 | 456,656 |
| Jul 24, 2026 | 1.44 | 1.45 | 1.40 | 1.41 | 1.41 | 446,401 |
| Jul 23, 2026 | 1.42 | 1.45 | 1.40 | 1.43 | 1.43 | 439,302 |
| Jul 22, 2026 | 1.48 | 1.49 | 1.43 | 1.43 | 1.43 | 349,824 |
| Jul 21, 2026 | 1.43 | 1.48 | 1.40 | 1.47 | 1.47 | 376,642 |
| Jul 20, 2026 | 1.39 | 1.43 | 1.38 | 1.42 | 1.42 | 365,434 |
| Jul 17, 2026 | 1.38 | 1.41 | 1.36 | 1.40 | 1.40 | 575,760 |
| Jul 16, 2026 | 1.46 | 1.46 | 1.37 | 1.39 | 1.39 | 608,902 |
| Jul 15, 2026 | 1.48 | 1.48 | 1.42 | 1.44 | 1.44 | 628,818 |
| Jul 14, 2026 | 1.48 | 1.49 | 1.44 | 1.45 | 1.45 | 421,901 |
| Jul 13, 2026 | 1.50 | 1.54 | 1.46 | 1.47 | 1.47 | 553,146 |
| Jul 10, 2026 | 1.59 | 1.64 | 1.52 | 1.54 | 1.54 | 930,771 |
| Jul 9, 2026 | 1.62 | 1.65 | 1.57 | 1.63 | 1.63 | 1,228,831 |
| Jul 8, 2026 | 1.63 | 1.69 | 1.60 | 1.65 | 1.65 | 1,610,711 |
| Jul 7, 2026 | 1.56 | 1.71 | 1.53 | 1.67 | 1.67 | 1,526,059 |
| Jul 6, 2026 | 1.44 | 1.60 | 1.43 | 1.56 | 1.56 | 1,535,256 |
| Jul 2, 2026 | 1.44 | 1.49 | 1.42 | 1.45 | 1.45 | 851,333 |
| Jul 1, 2026 | 1.40 | 1.49 | 1.40 | 1.44 | 1.44 | 613,586 |
| Jun 30, 2026 | 1.44 | 1.46 | 1.39 | 1.40 | 1.40 | 664,881 |
| Jun 29, 2026 | 1.50 | 1.53 | 1.43 | 1.45 | 1.45 | 1,055,818 |
| Jun 26, 2026 | 1.48 | 1.52 | 1.46 | 1.50 | 1.50 | 4,460,508 |
| Jun 25, 2026 | 1.52 | 1.56 | 1.48 | 1.48 | 1.48 | 513,945 |
| Jun 24, 2026 | 1.50 | 1.55 | 1.48 | 1.52 | 1.52 | 804,832 |
| Jun 23, 2026 | 1.44 | 1.52 | 1.44 | 1.46 | 1.46 | 499,546 |
| Jun 22, 2026 | 1.47 | 1.56 | 1.43 | 1.48 | 1.48 | 922,238 |
| Jun 18, 2026 | 1.42 | 1.50 | 1.39 | 1.48 | 1.48 | 1,288,484 |
| Jun 17, 2026 | 1.38 | 1.42 | 1.36 | 1.39 | 1.39 | 646,278 |
| Jun 16, 2026 | 1.37 | 1.39 | 1.33 | 1.38 | 1.38 | 1,116,591 |
| Jun 15, 2026 | 1.42 | 1.45 | 1.36 | 1.36 | 1.36 | 708,531 |
| Jun 12, 2026 | 1.42 | 1.45 | 1.39 | 1.40 | 1.40 | 506,402 |
| Jun 11, 2026 | 1.36 | 1.44 | 1.33 | 1.42 | 1.42 | 787,130 |
| Jun 10, 2026 | 1.43 | 1.45 | 1.35 | 1.36 | 1.36 | 657,516 |
| Jun 9, 2026 | 1.44 | 1.49 | 1.42 | 1.42 | 1.42 | 691,516 |
| Jun 8, 2026 | 1.47 | 1.49 | 1.42 | 1.42 | 1.42 | 622,356 |
| Jun 5, 2026 | 1.57 | 1.57 | 1.44 | 1.45 | 1.45 | 908,734 |
| Jun 4, 2026 | 1.50 | 1.59 | 1.50 | 1.57 | 1.57 | 839,897 |
| Jun 3, 2026 | 1.52 | 1.52 | 1.46 | 1.47 | 1.47 | 1,036,547 |
| Jun 2, 2026 | 1.56 | 1.56 | 1.51 | 1.52 | 1.52 | 894,912 |
| Jun 1, 2026 | 1.60 | 1.64 | 1.56 | 1.57 | 1.57 | 817,379 |
| May 29, 2026 | 1.65 | 1.68 | 1.58 | 1.59 | 1.59 | 1,532,142 |
| May 28, 2026 | 1.65 | 1.67 | 1.63 | 1.65 | 1.65 | 495,902 |
| May 27, 2026 | 1.64 | 1.74 | 1.64 | 1.66 | 1.66 | 1,199,395 |
| May 26, 2026 | 1.65 | 1.72 | 1.63 | 1.64 | 1.64 | 1,268,869 |
| May 22, 2026 | 1.60 | 1.65 | 1.59 | 1.61 | 1.61 | 919,436 |
| May 21, 2026 | 1.49 | 1.60 | 1.48 | 1.57 | 1.57 | 1,393,131 |
| May 20, 2026 | 1.47 | 1.56 | 1.47 | 1.51 | 1.51 | 702,252 |
| May 19, 2026 | 1.49 | 1.50 | 1.46 | 1.48 | 1.48 | 1,375,858 |
| May 18, 2026 | 1.57 | 1.60 | 1.46 | 1.49 | 1.49 | 1,772,264 |
| May 15, 2026 | 1.61 | 1.65 | 1.55 | 1.57 | 1.57 | 1,507,776 |
| May 14, 2026 | 1.70 | 1.74 | 1.62 | 1.63 | 1.63 | 1,982,416 |
| May 13, 2026 | 1.73 | 1.79 | 1.60 | 1.71 | 1.71 | 2,407,283 |
| May 12, 2026 | 1.75 | 1.82 | 1.62 | 1.71 | 1.71 | 3,463,734 |
| May 11, 2026 | 1.89 | 2.10 | 1.87 | 1.95 | 1.95 | 3,713,116 |
| May 8, 2026 | 1.77 | 1.80 | 1.74 | 1.75 | 1.75 | 676,080 |
| May 7, 2026 | 1.76 | 1.77 | 1.71 | 1.76 | 1.76 | 921,646 |
| May 6, 2026 | 1.81 | 1.87 | 1.75 | 1.75 | 1.75 | 1,288,325 |
| May 5, 2026 | 1.74 | 1.80 | 1.74 | 1.79 | 1.79 | 874,839 |
| May 4, 2026 | 1.78 | 1.82 | 1.73 | 1.73 | 1.73 | 717,576 |
| May 1, 2026 | 1.75 | 1.80 | 1.73 | 1.80 | 1.80 | 560,694 |
| Apr 30, 2026 | 1.74 | 1.83 | 1.74 | 1.77 | 1.77 | 523,616 |
| Apr 29, 2026 | 1.75 | 1.75 | 1.70 | 1.74 | 1.74 | 665,403 |
| Apr 28, 2026 | 1.79 | 1.85 | 1.75 | 1.77 | 1.77 | 624,571 |
| Apr 27, 2026 | 1.75 | 1.89 | 1.74 | 1.84 | 1.84 | 1,036,079 |
| Apr 24, 2026 | 1.76 | 1.77 | 1.72 | 1.75 | 1.75 | 906,351 |
| Apr 23, 2026 | 1.81 | 1.81 | 1.69 | 1.76 | 1.76 | 1,379,828 |
| Apr 22, 2026 | 1.85 | 1.85 | 1.77 | 1.80 | 1.80 | 816,765 |
| Apr 21, 2026 | 1.98 | 2.00 | 1.81 | 1.82 | 1.82 | 1,938,693 |
| Apr 20, 2026 | 1.96 | 2.02 | 1.93 | 1.99 | 1.99 | 764,203 |
| Apr 17, 2026 | 1.94 | 1.99 | 1.88 | 1.98 | 1.98 | 1,755,139 |
| Apr 16, 2026 | 1.87 | 1.96 | 1.85 | 1.90 | 1.90 | 1,645,020 |
| Apr 15, 2026 | 1.79 | 1.88 | 1.76 | 1.88 | 1.88 | 1,069,962 |
| Apr 14, 2026 | 1.71 | 1.82 | 1.71 | 1.80 | 1.80 | 1,031,680 |
| Apr 13, 2026 | 1.67 | 1.71 | 1.62 | 1.71 | 1.71 | 939,464 |
| Apr 10, 2026 | 1.64 | 1.69 | 1.64 | 1.68 | 1.68 | 556,774 |
| Apr 9, 2026 | 1.69 | 1.70 | 1.61 | 1.65 | 1.65 | 990,376 |
| Apr 8, 2026 | 1.76 | 1.76 | 1.66 | 1.70 | 1.70 | 816,740 |
| Apr 7, 2026 | 1.67 | 1.71 | 1.59 | 1.67 | 1.67 | 735,105 |
| Apr 6, 2026 | 1.73 | 1.78 | 1.66 | 1.67 | 1.67 | 620,552 |
| Apr 2, 2026 | 1.70 | 1.75 | 1.68 | 1.73 | 1.73 | 537,249 |
| Apr 1, 2026 | 1.72 | 1.79 | 1.70 | 1.74 | 1.74 | 793,803 |
| Mar 31, 2026 | 1.64 | 1.73 | 1.63 | 1.69 | 1.69 | 865,546 |
| Mar 30, 2026 | 1.65 | 1.68 | 1.58 | 1.60 | 1.60 | 806,458 |
| Mar 27, 2026 | 1.63 | 1.68 | 1.61 | 1.63 | 1.63 | 684,213 |
| Mar 26, 2026 | 1.74 | 1.78 | 1.66 | 1.66 | 1.66 | 692,741 |
| Mar 25, 2026 | 1.73 | 1.85 | 1.69 | 1.77 | 1.77 | 2,295,966 |
| Mar 24, 2026 | 1.62 | 1.75 | 1.60 | 1.71 | 1.71 | 3,107,371 |
| Mar 23, 2026 | 1.56 | 1.65 | 1.54 | 1.64 | 1.64 | 1,256,353 |
| Mar 20, 2026 | 1.63 | 1.63 | 1.52 | 1.52 | 1.52 | 2,667,206 |
| Mar 19, 2026 | 1.57 | 1.62 | 1.54 | 1.61 | 1.61 | 900,426 |
| Mar 18, 2026 | 1.65 | 1.66 | 1.57 | 1.58 | 1.58 | 1,401,837 |
| Mar 17, 2026 | 1.66 | 1.73 | 1.66 | 1.68 | 1.68 | 963,287 |
| Mar 16, 2026 | 1.66 | 1.70 | 1.62 | 1.66 | 1.66 | 846,888 |
| Mar 13, 2026 | 1.69 | 1.76 | 1.60 | 1.63 | 1.63 | 1,164,578 |
| Mar 12, 2026 | 1.73 | 1.75 | 1.61 | 1.69 | 1.69 | 2,111,505 |
| Mar 11, 2026 | 1.97 | 2.00 | 1.78 | 1.78 | 1.78 | 1,510,219 |
| Mar 10, 2026 | 1.86 | 2.06 | 1.81 | 1.95 | 1.95 | 2,424,904 |
| Mar 9, 2026 | 1.82 | 1.95 | 1.80 | 1.93 | 1.93 | 2,234,121 |
| Mar 6, 2026 | 1.75 | 1.83 | 1.74 | 1.82 | 1.82 | 1,641,141 |
| Mar 5, 2026 | 1.74 | 1.83 | 1.74 | 1.76 | 1.76 | 1,149,722 |
| Mar 4, 2026 | 1.69 | 1.81 | 1.68 | 1.76 | 1.76 | 1,723,242 |
| Mar 3, 2026 | 1.62 | 1.70 | 1.57 | 1.65 | 1.65 | 1,119,924 |
| Mar 2, 2026 | 1.59 | 1.68 | 1.58 | 1.65 | 1.65 | 1,052,573 |
| Feb 27, 2026 | 1.65 | 1.69 | 1.65 | 1.67 | 1.67 | 1,039,075 |
| Feb 26, 2026 | 1.69 | 1.70 | 1.63 | 1.69 | 1.69 | 636,534 |
| Feb 25, 2026 | 1.68 | 1.74 | 1.66 | 1.68 | 1.68 | 778,222 |
| Feb 24, 2026 | 1.64 | 1.70 | 1.62 | 1.67 | 1.67 | 949,872 |
| Feb 23, 2026 | 1.64 | 1.65 | 1.59 | 1.62 | 1.62 | 1,307,526 |
| Feb 20, 2026 | 1.70 | 1.74 | 1.62 | 1.63 | 1.63 | 1,368,524 |
| Feb 19, 2026 | 1.61 | 1.73 | 1.60 | 1.71 | 1.71 | 2,358,700 |
| Feb 18, 2026 | 1.64 | 1.66 | 1.59 | 1.63 | 1.63 | 1,851,523 |
| Feb 17, 2026 | 1.65 | 1.69 | 1.60 | 1.61 | 1.61 | 2,768,228 |
| Feb 13, 2026 | 1.70 | 1.79 | 1.58 | 1.61 | 1.61 | 10,920,317 |
| Feb 12, 2026 | 2.06 | 2.07 | 1.98 | 2.01 | 2.01 | 911,008 |
| Feb 11, 2026 | 2.11 | 2.12 | 1.97 | 2.04 | 2.04 | 885,959 |
| Feb 10, 2026 | 2.07 | 2.20 | 2.05 | 2.11 | 2.11 | 805,723 |
| Feb 9, 2026 | 2.13 | 2.16 | 1.95 | 2.06 | 2.06 | 1,479,656 |
| Feb 6, 2026 | 2.15 | 2.19 | 2.02 | 2.14 | 2.14 | 2,444,996 |
| Feb 5, 2026 | 2.20 | 2.24 | 2.07 | 2.09 | 2.09 | 1,692,772 |
| Feb 4, 2026 | 2.28 | 2.42 | 2.18 | 2.22 | 2.22 | 2,070,720 |
| Feb 3, 2026 | 2.18 | 2.25 | 2.10 | 2.22 | 2.22 | 1,672,465 |
| Feb 2, 2026 | 2.13 | 2.31 | 2.11 | 2.17 | 2.17 | 1,799,183 |
| Jan 30, 2026 | 2.30 | 2.37 | 2.13 | 2.16 | 2.16 | 1,924,213 |
| Jan 29, 2026 | 2.19 | 2.39 | 2.08 | 2.33 | 2.33 | 2,250,674 |
| Jan 28, 2026 | 2.51 | 2.57 | 2.21 | 2.21 | 2.21 | 3,440,148 |
| Jan 27, 2026 | 2.31 | 2.62 | 2.17 | 2.51 | 2.51 | 8,860,269 |
| Jan 26, 2026 | 2.02 | 2.30 | 2.00 | 2.28 | 2.28 | 7,553,860 |
| Jan 23, 2026 | 1.86 | 2.17 | 1.83 | 2.06 | 2.06 | 21,606,170 |
| Jan 22, 2026 | 1.64 | 1.67 | 1.57 | 1.59 | 1.59 | 2,810,327 |
| Jan 21, 2026 | 1.56 | 1.64 | 1.55 | 1.64 | 1.64 | 843,112 |
| Jan 20, 2026 | 1.56 | 1.61 | 1.51 | 1.55 | 1.55 | 1,263,766 |
| Jan 16, 2026 | 1.67 | 1.67 | 1.59 | 1.60 | 1.60 | 986,079 |
| Jan 15, 2026 | 1.60 | 1.67 | 1.56 | 1.66 | 1.66 | 1,334,813 |
| Jan 14, 2026 | 1.68 | 1.72 | 1.60 | 1.60 | 1.60 | 873,625 |
| Jan 13, 2026 | 1.66 | 1.71 | 1.58 | 1.70 | 1.70 | 1,742,555 |
| Jan 12, 2026 | 1.71 | 1.72 | 1.58 | 1.65 | 1.65 | 1,117,800 |
| Jan 9, 2026 | 1.54 | 1.77 | 1.52 | 1.69 | 1.69 | 3,836,160 |
| Jan 8, 2026 | 1.43 | 1.55 | 1.38 | 1.53 | 1.53 | 2,320,464 |
| Jan 7, 2026 | 1.45 | 1.53 | 1.37 | 1.43 | 1.43 | 977,629 |
| Jan 6, 2026 | 1.47 | 1.49 | 1.35 | 1.36 | 1.36 | 1,110,603 |
| Jan 5, 2026 | 1.37 | 1.52 | 1.37 | 1.44 | 1.44 | 2,658,065 |
| Jan 2, 2026 | 1.42 | 1.44 | 1.36 | 1.37 | 1.37 | 649,436 |
| Dec 31, 2025 | 1.41 | 1.49 | 1.39 | 1.42 | 1.42 | 1,167,606 |
| Dec 30, 2025 | 1.35 | 1.46 | 1.35 | 1.41 | 1.41 | 1,304,901 |
| Dec 29, 2025 | 1.30 | 1.34 | 1.27 | 1.34 | 1.34 | 715,850 |
| Dec 26, 2025 | 1.35 | 1.35 | 1.30 | 1.33 | 1.33 | 292,867 |
| Dec 24, 2025 | 1.32 | 1.37 | 1.32 | 1.34 | 1.34 | 318,160 |
| Dec 23, 2025 | 1.40 | 1.40 | 1.30 | 1.32 | 1.32 | 793,971 |
| Dec 22, 2025 | 1.37 | 1.43 | 1.35 | 1.40 | 1.40 | 558,468 |
| Dec 19, 2025 | 1.36 | 1.40 | 1.34 | 1.36 | 1.36 | 1,063,199 |
| Dec 18, 2025 | 1.37 | 1.40 | 1.35 | 1.36 | 1.36 | 645,618 |
| Dec 17, 2025 | 1.38 | 1.41 | 1.35 | 1.35 | 1.35 | 756,271 |
| Dec 16, 2025 | 1.38 | 1.40 | 1.32 | 1.39 | 1.39 | 802,227 |
| Dec 15, 2025 | 1.36 | 1.40 | 1.30 | 1.39 | 1.39 | 751,942 |
| Dec 12, 2025 | 1.43 | 1.45 | 1.34 | 1.35 | 1.35 | 872,122 |
| Dec 11, 2025 | 1.33 | 1.44 | 1.31 | 1.43 | 1.43 | 1,131,813 |
| Dec 10, 2025 | 1.30 | 1.34 | 1.28 | 1.33 | 1.33 | 1,038,085 |
| Dec 9, 2025 | 1.30 | 1.32 | 1.27 | 1.29 | 1.29 | 1,085,501 |
| Dec 8, 2025 | 1.23 | 1.35 | 1.23 | 1.28 | 1.28 | 1,773,230 |
| Dec 5, 2025 | 1.25 | 1.27 | 1.18 | 1.20 | 1.20 | 1,018,424 |
| Dec 4, 2025 | 1.22 | 1.25 | 1.20 | 1.23 | 1.23 | 831,116 |
| Dec 3, 2025 | 1.18 | 1.25 | 1.15 | 1.22 | 1.22 | 990,787 |
| Dec 2, 2025 | 1.28 | 1.32 | 1.16 | 1.16 | 1.16 | 949,313 |
| Dec 1, 2025 | 1.31 | 1.33 | 1.26 | 1.27 | 1.27 | 802,809 |
| Nov 28, 2025 | 1.34 | 1.39 | 1.33 | 1.36 | 1.36 | 750,018 |
| Nov 26, 2025 | 1.27 | 1.32 | 1.25 | 1.31 | 1.31 | 972,847 |
| Nov 25, 2025 | 1.29 | 1.31 | 1.24 | 1.28 | 1.28 | 566,544 |
| Nov 24, 2025 | 1.15 | 1.30 | 1.15 | 1.28 | 1.28 | 1,504,270 |
| Nov 21, 2025 | 1.09 | 1.17 | 1.09 | 1.16 | 1.16 | 881,213 |
| Nov 20, 2025 | 1.18 | 1.22 | 1.09 | 1.10 | 1.10 | 1,151,738 |
| Nov 19, 2025 | 1.20 | 1.23 | 1.16 | 1.16 | 1.16 | 622,801 |
| Nov 18, 2025 | 1.10 | 1.25 | 1.10 | 1.21 | 1.21 | 1,277,845 |
| Nov 17, 2025 | 1.18 | 1.24 | 1.10 | 1.13 | 1.13 | 1,771,078 |
| Nov 14, 2025 | 1.10 | 1.23 | 1.09 | 1.19 | 1.19 | 1,478,637 |
| Nov 13, 2025 | 1.34 | 1.34 | 1.25 | 1.26 | 1.26 | 1,612,933 |
| Nov 12, 2025 | 1.36 | 1.39 | 1.28 | 1.36 | 1.36 | 1,597,710 |
| Nov 11, 2025 | 1.26 | 1.36 | 1.26 | 1.35 | 1.35 | 2,101,872 |
| Nov 10, 2025 | 1.37 | 1.43 | 1.23 | 1.26 | 1.26 | 2,053,364 |
| Nov 7, 2025 | 1.35 | 1.40 | 1.29 | 1.34 | 1.34 | 2,921,422 |
| Nov 6, 2025 | 1.54 | 1.60 | 1.42 | 1.49 | 1.49 | 2,012,197 |
| Nov 5, 2025 | 1.54 | 1.61 | 1.54 | 1.56 | 1.56 | 1,143,959 |
| Nov 4, 2025 | 1.55 | 1.59 | 1.39 | 1.55 | 1.55 | 1,594,060 |
| Nov 3, 2025 | 1.69 | 1.72 | 1.57 | 1.60 | 1.60 | 1,009,765 |
| Oct 31, 2025 | 1.68 | 1.71 | 1.65 | 1.68 | 1.68 | 774,159 |
| Oct 30, 2025 | 1.73 | 1.78 | 1.68 | 1.70 | 1.70 | 784,682 |
| Oct 29, 2025 | 1.73 | 1.80 | 1.69 | 1.73 | 1.73 | 1,201,403 |
| Oct 28, 2025 | 1.59 | 1.75 | 1.59 | 1.74 | 1.74 | 1,769,073 |
| Oct 27, 2025 | 1.65 | 1.69 | 1.59 | 1.60 | 1.60 | 864,991 |
| Oct 24, 2025 | 1.68 | 1.70 | 1.64 | 1.65 | 1.65 | 549,709 |
| Oct 23, 2025 | 1.69 | 1.72 | 1.65 | 1.67 | 1.67 | 451,630 |
| Oct 22, 2025 | 1.74 | 1.74 | 1.64 | 1.68 | 1.68 | 844,034 |
| Oct 21, 2025 | 1.76 | 1.82 | 1.72 | 1.74 | 1.74 | 538,606 |
| Oct 20, 2025 | 1.68 | 1.79 | 1.67 | 1.79 | 1.79 | 1,086,473 |
| Oct 17, 2025 | 1.70 | 1.71 | 1.63 | 1.65 | 1.65 | 839,866 |
| Oct 16, 2025 | 1.78 | 1.85 | 1.70 | 1.71 | 1.71 | 1,172,548 |
| Oct 15, 2025 | 1.73 | 1.80 | 1.69 | 1.78 | 1.78 | 875,672 |
| Oct 14, 2025 | 1.70 | 1.73 | 1.66 | 1.70 | 1.70 | 758,208 |
| Oct 13, 2025 | 1.66 | 1.74 | 1.63 | 1.73 | 1.73 | 895,612 |
| Oct 10, 2025 | 1.85 | 1.87 | 1.67 | 1.67 | 1.67 | 1,581,802 |
| Oct 9, 2025 | 1.78 | 1.89 | 1.78 | 1.82 | 1.82 | 1,640,877 |
| Oct 8, 2025 | 1.72 | 1.78 | 1.69 | 1.76 | 1.76 | 1,082,347 |
| Oct 7, 2025 | 1.69 | 1.72 | 1.63 | 1.71 | 1.71 | 1,145,533 |
| Oct 6, 2025 | 1.67 | 1.79 | 1.67 | 1.70 | 1.70 | 1,350,389 |
| Oct 3, 2025 | 1.67 | 1.70 | 1.61 | 1.64 | 1.64 | 715,578 |
| Oct 2, 2025 | 1.62 | 1.67 | 1.57 | 1.66 | 1.66 | 824,985 |
| Oct 1, 2025 | 1.60 | 1.64 | 1.56 | 1.62 | 1.62 | 1,009,167 |
| Sep 30, 2025 | 1.70 | 1.72 | 1.59 | 1.64 | 1.64 | 940,080 |
| Sep 29, 2025 | 1.55 | 1.71 | 1.48 | 1.70 | 1.70 | 2,245,629 |
| Sep 26, 2025 | 1.43 | 1.51 | 1.37 | 1.50 | 1.50 | 1,567,202 |
| Sep 25, 2025 | 1.57 | 1.57 | 1.43 | 1.45 | 1.45 | 1,231,311 |
| Sep 24, 2025 | 1.56 | 1.58 | 1.48 | 1.58 | 1.58 | 1,199,310 |
| Sep 23, 2025 | 1.58 | 1.63 | 1.53 | 1.56 | 1.56 | 974,022 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
Need daily prices for every ticker, in code?
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver API
Coherus Oncology, Inc. Common Stock Executive Compensation
We estimate that -- received a compensation of -- in --, making them the highest paid executive at CHRS, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|